GLP-1 drugs could have been developed decades earlier, but regulatory and system-level choke points made it costly and cumbersome to test them, demonstrating how process barriers inhibit innovation.

factualpending

Speaker

Ezra Klein

Evidence Quote

“We could have had the GLP-1s decades ago. Um but there are a lot of reasons within the system that, you know, it would have been costly to try that out.”

Source

Ezra Klein on the Abundance Agenda | Conversations with Tyler— Mercatus Center
Created: 8/11/2026, 6:51:20 AM

Your notes

Loading notes...